[Targeted therapy in inflammatory disease: cytokines].
Summarizing 15 years of therapeutic development of a discipline into a few lines is not an easy thing to do. There are many potential targets involved in the inflammatory of auto-immune diseases. Due to the development of biotherapies the choice has become larger, and it is now possible to target practically any molecule (cytokine, chemokine or surface receptor for example). Cytokines represent the first example of therapeutic target that played a major role in the revolution of our discipline. The first part of presentation will focus on the pro-inflammatory cytokines (TNFalpha, and interleukines 1 and 6). We shall then, detail the development of a new cytokinic target: BLyS (B lymphocyte stimulator) whose role in the autoimmune diseases appeared recently.
Service de Rhumatologie, CHU de Liège, Belgique.
C
C
von Frenckell
M G
MG
Malaise
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy
D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines